Back to top

Crispr Therapeutics AG (CRSP) Gets a Buy from William Blair

William Blair analyst Sami Corwin maintained a Buy rating on Crispr Therapeutics AG yesterday. The company’s shares closed yesterday at $57.72. Acc...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

CRISPR Therapeutics AG (CRSP)